Corrigendum: Diabetes mellitus heightens the risk of hepatocellular carcinoma except in patients with hepatitis C cirrhosis (American Journal of Gastroenterology (2016) 111 (1573-1580) DOI: 10.1038/ajg.2016.330);Diabetes mellitus heightens the risk of hepatocellular carcinoma except in patients with hepatitis C cirrhosis

American Journal of Gastroenterology

Volumn 111, Issue 11, 2016, Pages 1573-1580

  Yang, Ju Dong ^a   Mohamed, Hager Amed ^a   Cvinar, Jessica L ^a   Gores, Gregory J ^a   Roberts, Lewis R ^a   Kim, W Ray ^b  

^a MAYO CLINIC   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER RISK; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAZARD RATIO; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; ULTRASOUND; CARCINOMA, HEPATOCELLULAR; CHOLANGITIS, SCLEROSING; COMPLICATION; HEPATITIS C, CHRONIC; HEPATITIS, AUTOIMMUNE; LIVER CIRRHOSIS, ALCOHOLIC; LIVER CIRRHOSIS, BILIARY; LIVER NEOPLASMS; NON-ALCOHOLIC FATTY LIVER DISEASE; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; CARCINOMA, HEPATOCELLULAR; CHOLANGITIS, SCLEROSING; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C, CHRONIC; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS; LIVER CIRRHOSIS, ALCOHOLIC; LIVER CIRRHOSIS, BILIARY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84982162422     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.463     Document Type: Erratum

References (40)

1. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485-91.
2. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 2010; 7: 448-58.
3. Yang JD, Harmsen WS, Slettedahl SW et al. Factors that affect risk for hepatocellular carcinoma and effects of surveillance. Clin Gastroenterol Hepatol 2011; 9: 617-23.e1.
4. Yang JD, Kim B, Sanderson SO et al. Hepatocellular carcinoma in Olmsted County, Minnesota, 1976-2008. Mayo Clin Proc 2012; 87: 9-16.
5. Welzel TM, Graubard BI, Quraishi S et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol 2013; 108: 1314-21.
6. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006; 4: 369-80.
7. Wang P, Kang D, Cao W et al. Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. Diabetes Metab Res Rev 2012; 28: 109-22.
8. Gentile S, Loguercio C, Marmo R et al. Incidence of altered glucose tolerance in liver cirrhosis. Diabetes Res Clin Pract 1993; 22: 37-44.
9. Veldt BJ, Chen W, Heathcote EJ et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008; 47: 1856-62.
10. Chen CT, Chen JY, Wang JH et al. Diabetes mellitus, metabolic syndrome and obesity are not significant risk factors for hepatocellular carcinoma in an HBV- and HCV-endemic area of Southern Taiwan. Kaohsiung J Med Sci 2013; 29: 451-9.
11. Ko WH, Chiu SY, Yang KC et al. Diabetes, hepatitis virus infection and hepatocellular carcinoma: a case-control study in hepatitis endemic area. Hepatol Res 2012; 42: 774-81.
12. Tung HD, Wang JH, Tseng PL et al. Neither diabetes mellitus nor overweight is a risk factor for hepatocellular carcinoma in a dual HBV and HCV endemic area: community cross-sectional and case-control studies. Am J Gastroenterol 2010; 105: 624-31.
13. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol 2008; 49: 831-44.
14. Di Bisceglie AM, Shiffman ML, Everson GT et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 2429-41.
15. Lok AS, Everhart JE, Wright EC et al. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011; 140: 840-9; quiz e12.
16. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
17. Sangiovanni A, Manini MA, Iavarone M et al. The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010; 59: 638-44.
18. Khalili K, KT JH, Haider MA et al. Implementation of AASLD hepatocellular carcinoma practice guideline in North America: two years of experience. Hepatology 2008; 48: 362A.
19. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52.
20. Jee SH, Ohrr H, Sull JW et al. Fasting serum glucose level and cancer risk in Korean men and women. JAMA 2005; 293: 194-202.
21. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45.
22. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-91.
23. Hirosumi J, Tuncman G, Chang L et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-6.
24. Sakurai T, Maeda S, Chang L et al. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci USA 2006; 103: 10544-51.
25. Hui L, Zatloukal K, Scheuch H et al. Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. J Clin Invest 2008; 118: 3943-53.
26. Chen F, Castranova V. Beyond apoptosis of JNK1 in liver cancer. Cell Cycle 2009; 8: 1145-7.
27. Arase Y, Kobayashi M, Suzuki F et al. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 2013; 57: 964-73.
28. Ohata K, Hamasaki K, Toriyama K et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003; 97: 3036-43.
29. Hui JM, Sud A, Farrell GC et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003; 125: 1695-704.
30. Petrides AS, Vogt C, Schulze-Berge D et al. Pathogenesis of glucose intolerance and diabetes mellitus in cirrhosis. Hepatology 1994; 19: 616-27.
31. Petrides AS, Stanley T, Matthews DE et al. Insulin resistance in cirrhosis: prolonged reduction of hyperinsulinemia normalizes insulin sensitivity. Hepatology 1998; 28: 141-9.
32. Perseghin G, Mazzaferro V, Sereni LP et al. Contribution of reduced insulin sensitivity and secretion to the pathogenesis of hepatogenous diabetes: effect of liver transplantation. Hepatology 2000; 31: 694-703.
33. Deschenes M, Somberg KA. Effect of transjugular intrahepatic portosystemic shunt (TIPS) on glycemic control in cirrhotic patients with diabetes mellitus. Am J Gastroenterol 1998; 93: 483.
34. Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med 2007; 120: 829-34.
35. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-32.
36. Svegliati-Baroni G, RidolfiF, Di Sario A et al. Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways. Hepatology 1999; 29: 1743-51.
37. Paradis V, Dargere D, Vidaud M et al. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 1999; 30: 968-76.
38. Paradis V, Perlemuter G, Bonvoust F et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 2001; 34: 738-44.
39. Flemming JA, Yang JD, VittinghoffE et al. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer 2014; 120: 3485-93.
40. Yang JD, Kim WR, Coelho R et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. Clin Gastroenterol Hepatology 2011; 9: 64-70.